The Cooper Companies, Inc. (NASDAQ:COO) Shares Bought by Sumitomo Life Insurance Co.

Sumitomo Life Insurance Co. grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 3.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 11,106 shares of the medical device company’s stock after purchasing an additional 328 shares during the period. Sumitomo Life Insurance Co.’s holdings in Cooper Companies were worth $1,225,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of COO. Benjamin F. Edwards & Company Inc. lifted its position in Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 174 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 208 shares during the last quarter. Innealta Capital LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at about $25,000. Crewe Advisors LLC grew its stake in Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the last quarter. Finally, Clearstead Trust LLC acquired a new position in Cooper Companies during the first quarter worth approximately $36,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Morgan Stanley raised their price objective on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 10th. Jefferies Financial Group raised shares of Cooper Companies from a “hold” rating to a “buy” rating and upped their target price for the company from $107.00 to $115.00 in a report on Tuesday, July 16th. Wells Fargo & Company raised their price target on Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $115.00.

Cooper Companies Stock Up 0.0 %

Cooper Companies stock opened at $108.56 on Thursday. The stock’s 50 day moving average price is $103.71 and its 200 day moving average price is $96.31. The company has a market cap of $21.62 billion, a PE ratio of 63.86, a price-to-earnings-growth ratio of 2.56 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18. The Cooper Companies, Inc. has a 1-year low of $75.93 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. During the same period in the prior year, the company posted $0.84 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, sell-side analysts predict that The Cooper Companies, Inc. will post 3.65 EPS for the current fiscal year.

Insider Buying and Selling at Cooper Companies

In related news, COO Daniel G. Mcbride sold 114,992 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now owns 44,696 shares in the company, valued at $4,714,534.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares in the company, valued at $4,714,534.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at approximately $520,488.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 256,373 shares of company stock valued at $27,637,427. Corporate insiders own 2.00% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.